Canada’s Intellectual Property Firm

Updates to Health Canada’s regulatory initiatives for 2022-2024, and amendments to Food and Drug Regulations (Exports and Transhipments of Drugs)

Authored byUrszula Wojtyra

Update: Health Canada’s “ Forward Regulatory Plan: 2023-2025” no longer lists some of the below initiatives, including the 2019 proposed amendments to the Food and Drug Regulations, “Regulations amending the Food and Drug Regulations (Improving Access to Generic Drugs)” (our previous article). We have been advised that the proposed amendments, as well as the 2021 to the proposed amendments to the Patented Medicines (Notice of Compliance) Regulations (Regulations Amending the Patented Medicines (Notice of Compliance) Regulations) (our previous article), are on hold.

Health Canada has updated its Forward Regulatory Plan: 2022-2024, providing information on regulatory initiatives Health Canada aims to propose or finalize over the next two years. Some of the new and updated initiatives pertaining to the Food and Drugs Act are highlighted below:


New initiatives:

Updated initiatives:

Health Canada has also updated its Regulatory Stock Review Plan: 2022-2024, which is a public list and description of planned reviews of regulations that Health Canada is proposing within a two-year period. The Stock Review Plan overlaps with some of the above described initiatives.

Should you have any questions, please do not hesitate to contact a member of the Life Sciences Regulatory & Compliance group.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.